Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK

Executive Summary

The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.


Related Content

Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World
Teva Advancing Two Advair Generics With Late 2017 Target
Strong 2Q And Fresh UK Investment Signal Few Brexit Blues at GSK
1Q Earnings Preview: What To Expect From US, EU Big Hitters
Witty On Pricing: Oncology 'No Safe Haven'
Witty Succumbs To Pressure: GSK Starts Formal Search For New CEO
Witty's Successor: The Shortlist
Timeline At The Top: What Witty Did At GSK
JP Morgan: Witty Happy To Be 'Promiscuous' To Rebuild GSK's Oncology Presence
Mylan's Generic Advair FDA Filing Puts Added Squeeze On GSK


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts